Secukinumab 150mg s.c.

BIOLOGICAL2 trials

Sponsors

Tongji Hospital, Taizhou Mabtech Pharmaceutical Co.,Ltd

Conditions

Ankylosing Spondylitis (AS)Psoriasis

Phase 1

Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers

Active, not recruitingNCT07254325

Taizhou Mabtech Pharmaceutical Co.,LtdPsoriasis

Start: 2025-12-15End: 2026-06-01Target: 114Updated: 2026-05-08

Phase 4

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

RecruitingNCT05303285

Tongji HospitalAnkylosing Spondylitis (AS)

Start: 2024-06-14End: 2026-08-31Target: 100Updated: 2026-01-27